How did OMER's Q4 2024 expenses impact its net profit?
5/7/2025 05:43pm
Omeros Corporation's (OMER) Q4 2024 financial results show that the company incurred $23.32 million in Research and Development (R&D) expenses and reported a net loss of $31.36 million for the period.
The significant R&D expenses reflect Omeros' ongoing investment in developing new pharmaceutical products, which is a critical component of its business model. However, the negative net income indicates that the company has not yet achieved profitability in the quarter, as the expenses outweighed the revenue.
|code|Ticker|Name|Date|R&D Expenses|Net Income|market_code|
|---|---|---|---|---|---|---|
|OMER|OMER.O|Omeros|2024 Q1|2.677E7|-3.7184E7|185|
|OMER|OMER.O|Omeros|2024 Q2|4.5349E7|-5.6041E7|185|
|OMER|OMER.O|Omeros|2024 Q3|2.4084E7|-3.2232E7|185|
|OMER|OMER.O|Omeros|2024 Q4|2.332E7|-3.1358E7|185|